Randomized, openlabel, phase 3 study in subjects with relapsed and refractory multiple myeloma receiving carfilzomib in combination with dexamethasone, comparing onceweekly versus twiceweekly carfilzomib dosing trial evaluated approximately 478 patients with relapsed and refractory multiple myeloma who have received at least. Patients received carfilzomib by intravenous infusion over 2 to 10 minutes at a dose of 20 mgm2. Ninlaro ixazomib capsules, for oral use hepatotoxicity. Multiple myeloma mm is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance mgus to plasma cell leukemia. Twice weekly 2056 mgm2 regimen by 30minute infusion. Store in accordance with information listed on the product insert. Carfilzomib is associated with a low rate of serum enzyme elevations during treatment and has been implicated to rare instances of clinically apparent, acute liver injury some of which have been fatal. What do i need to tell my doctor before i take carfilzomib. Kyprolis carfilzomib for relapsed or refractory multiple. Carfilzomib is classified as a proteasome inhibitor. Oct 28, 2019 carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions. Kyprolis carfilzomib for relapsed multiple myeloma treatment.
Sep, 2019 carfilzomib kyprolis news and resources for multiple myeloma patients, caregivers, and others interested in carfilzomib and multiple myeloma. Carfilzomib for previously treated multiple myeloma nice. It uses a similar set of steps to inserting as an image, but does something different as a result. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. Kyprolis is a sterile, white to offwhite lyophilized powder and is available as a singledose 60 mg vial.
Dec 17, 2014 carfilzomib for the treatment of patients with advanced neuroendocrine cancers the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Highlightsof prescribing information these highlights do not include all the information needed to use kyprolis safely and effectively. Immune thrombocytopenia itp treatment nplate romiplostim. Incidence and management of adverse events in patients with. Carfilzomib kyprolis news and resources for multiple myeloma patients, caregivers, and others interested in carfilzomib and multiple myeloma. Insert a pdf file as an object into a powerpoint presentation to insert a pdf file as an object into a powerpoint presentation, you make it available to those youre sharing the presentation with. Kyprolis summary of product characteristics smpc emc.
Highlights of prescribing information initiate promacta at. Carfilzomib is a secondgeneration proteasome inhibitor with welldocumented clinical activity as a single agent in patients with relapsedrefractory multiple myeloma. Administration kyprolis can be administered in a 50ml or 100ml intravenous bag of 5% dextrose injection, usp. Listing a study does not mean it has been evaluated by the u. Carfilzomib is a crystalline substance with a molecular weight of 719. Kyprolis, inncarfilzomib european medicines agency. Infusion time is 10 minutes and remains consistent throughout the regimen. After reconstitution, 1 ml of solution contains 2 mg of carfilzomib.
Kyprolis with lenalidomide for multiple myeloma details. Carfilzomib, a selective proteasome inhibitor approved in the usa in 2012, is a single agent for relapsed and refractory multiple myeloma. The nccn compendium is a derivative work of the nccn guidelines. Carfilzomib can partially overcome resistance in bortezomibrefractory patients and has significant efficacy in bortezomibnaive patients. Dec 04, 2019 a study showed that these patients taking carfilzomib with certain other drugs melphalan and prednisone had more very bad and sometimes deadly side effects compared to a certain other drug. Community harmonized assessment of myeloma patients via an integrated oncology network1 champion1 was a phase 12, multicenter a collaboration of community oncology networks, singlearm, doseescalation study investigating carfilzomib administered on a onceweekly schedule in combination with dexamethasone to patients with relapsed, or relapsed. Carfilzomib pharmacokinetics absorption bioavailability. Please see indication and important safety information. Kyprolis carfilzomib for injection, for intravenous use initial u. This medicinal product is subject to additional monitoring. A singlearm trial enrolled 266 patients with multiple myeloma refractory to the most recent therapy who had received prior treatment with bortezomib and an immunomodulatory agent imid. Daratumumab plus pomalidomide and dexamethasone pomdex was evaluated in patients with relapsedrefractory multiple myeloma with.
Side effects of kyprolis carfilzomib, warnings, uses. Carfilzomib kyprolis may be considered medically necessary for the fdaapproved indication of treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Auc is doseproportional over the dose range of 2036 mgm 2. Prior to each dose in cycle 1, give 250 ml to 500 ml of intravenous normal saline or other appropriate. First described in 1848, mm is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein m protein. Aug 24, 2017 daratumumab plus pomalidomide and dexamethasone pomdex was evaluated in patients with relapsedrefractory multiple myeloma with. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. Kyprolis is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma. In some cases, health care professionals may use the trade name kyprolis when referring to the generic drug name carfilzomib. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors. Promacta eltrombopag tablets, for oral use promacta eltrombopag for oral suspension initial u. Infuse over 10 or 30minutes depending on the kyprolis dose regimen see dosage and administration 2. Empliciti elotuzumab, when used with pd or rd, is a prescription treatment for certain adults with relapsed or refractory multiple myeloma. Moreau p, hullin c, garban f, yakoubagha i, benboubker l, attal m, et al.
Kyprolis is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions. Medication use recorded from informed consent through 30 days following the last dose of any study drug. Carfilzomib is the generic name for the trade name drug kyprolis. Kyprolis carfilzomib is an antineoplastic agent indicated to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with velcade bortezomib and an immunomodulatory therapy. Fda approves new kyprolis carfilzomib combination therapy for. Highlights of prescribing information these highlights do not include all the information needed to use promacta safely and effectively. Kyprolis carfilzomib is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. Do not use kyprolis if you are allergic to carfilzomib or any of the other ingredients of this medicine listed in section 6. Highlights of prescribing information these highlights. Velcade can cause damage to the nerves, a condition called peripheral neuropathy.
Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. The mtd of the regimen was dose level 1 carfilzomib 2027 mgm2, pomalidomide 4 mg, dexamethasone 40 mg. Independent, uptodate news and information for the multiple myeloma community. If patient starting dose was 10 mg daily, resume at 5 mg less than previous dose. Carfilzomib is an irreversible proteasome inhibitor and antineoplastic agent that is used in treatment of refractory multiple myeloma.
Do not mix with or administer as an infusion with other medicinal products. Kyprolis carfilzomib dose, indications, adverse effects. Carfilzomib for the treatment of patients with advanced. Carfilzomibdexamethasone versus bortezomibdexamethasone in. Accumulated treatment cost of new therapies in multiple myeloma. Three cases of druginduced thrombotic microangiopathy tma. Kyprolis carfilzomib for injection, for intravenous use. Revlimid lenalidomide is a prescription medicine, used to treat adults with multiple myeloma mm in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation a type of stem cell transplant that uses your own stem cells. Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the nterminal threoninecontaining active sites of the 20s proteasome, the proteolytic core particle within the 26s proteasome.
The printed package leaflet of the medicinal product must state the name and address of the. Dose carfilzomib at a maximum body surface area bsa of 2. Refer to the dexamethasone prescribing information for other information on that product. Hydrate patients to reduce the risk of renal toxicity and of tumor lysis syndrome tls.
Carfilzomib is in a class of medications called proteasome inhibitors. Evidencebased recommendations on carfilzomib kyprolis for treating multiple myeloma in adults. Nplate is a prescription medicine used to treat low blood platelet counts thrombocytopenia in adults with immune thrombocytopenia itp when certain medicines or surgery to remove your spleen have not worked well enough. As discussed in this emedtv resource, carfilzomib is used to treat a type of cancer called multiple myeloma. Phase 3 arrow study of onceweekly kyprolis carfilzomib. Synchronous trophozoites were treated with 100 nm or 1. Sep 28, 2012 carfilzomib is a secondgeneration proteasome inhibitor with welldocumented clinical activity as a single agent in patients with relapsedrefractory multiple myeloma.
Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. If you have an allergy to carfilzomib or any other part of carfilzomib. A phase 2 study of carfilzomib plus elotuzumab plus. Kyprolis is a sterile, white to offwhite lyophilized powder and is available as a singledose 10 mg, 30 mg or 60 mg vial. Carfilzomib marketed under the trade name kyprolis, developed by onyx pharmaceuticals is an anticancer drug acting as a selective proteasome inhibitor. Carfilzomib can partially overcome resistance in bortezomibrefractory patients and has significant efficacy in. Kyprolis carfilzomib dosing, indications, interactions.
Carfilzomib for relapsed or refractory multiple myeloma authors. Carfilzomib was initially fdaapproved in 2012 as monotherapy in myeloma patients who received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. Nov 20, 2019 you must read the package leaflet of all medicines that you take in combination with kyprolis so that you understand the information related to those medicines. Community harmonized assessment of myeloma patients via an integrated oncology network1 champion1 was a phase 12, multicenter a collaboration of community oncology networks, singlearm, doseescalation study investigating carfilzomib administered on a onceweekly schedule in combination with dexamethasone to patients with relapsed, or relapsed and refractory mm.
Parasites were placed in fresh media, and proteasome activities of all samples were determined by mv151 labeling at 10 hr after inhibitor washout. This article explains how this chemotherapy regimen works to kill cancer cells. Carfilzomib, pomalidomide, and dexamethasone for relapsed or. Carfilzomib for the treatment of patients with advanced neuroendocrine cancers the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. It also explains why this drug is only approved for adults. Highlightsof prescribing information kyprolis safely and. Kyprolis is a sterile, white to offwhite lyophilized powder and is. A study showed that these patients taking carfilzomib with certain other drugs melphalan and prednisone had more very bad and sometimes deadly side effects compared to a certain other drug. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of. Administration infuse over 10 or 30 minutes depending on the kyprolis dose regimen see dosage and administration 2. Kyprolis carfilzomib for relapsed multiple myeloma.
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib a consensus paper by the european myeloma. Daratumumab plus pomalidomide and dexamethasone in relapsed. Carfilzomib for relapsed or refractory multiple myeloma the lancet. Carfilzomib is administered as a 210minute infusion on days 1, 2, 8, 9, 15, and 16 of a 28day cycle at a starting dose of 20 mgm 2 for cycle 1 and a target dose of 27 mgm 2 thereafter. When combined with dexamethasone, kyprolis is administered intravenously as a 30 minute infusion on two consecutive days, each week for three weeks days 1, 2, 8, 9, 15, and 16 followed by a 12day rest period days 17 to 28 as shown in table 2. Carfilzomib injection is used alone and in combination with dexamethasone or lenalidomide revlimid and dexamethasone to treat people with multiple myeloma a type of cancer of the bone marrow who have already been treated with other medications. Treatments received, total dosage, responses, toxicities.
659 1309 174 1177 269 1578 1506 1072 1478 1422 1644 1523 413 1037 1609 144 150 1014 77 196 281 507 1363 236 758 474 418 360 1060 798 1326 962 27